Hims & Hers (HIMS: Q2 revenue shock, GLP‑1 slump and insider sale#
Hims & Hers recorded a sudden commercial reversal: compounded GLP‑1 revenue fell from $230.0M in Q1 to $190.0M in Q2 (a -17.39% sequential decline), shares traded down -4.04% intraday, and CEO Andrew Dudum sold roughly $33.4M of stock—events that compressed the company’s high‑growth narrative into a legal and regulatory reset.
Professional Market Analysis Platform
Unlock institutional-grade data with a free Monexa workspace. Upgrade whenever you need the full AI and DCF toolkit—your 7-day Pro trial starts after checkout.
Company disclosures put Q2 total revenue at $545 million, a -7.00% sequential decline; management attributed the deterioration primarily to off‑boarding of some GLP‑1 subscribers after the June 23 termination of the Novo Nordisk collaboration and a mix shift toward lower‑priced personalized GLP‑1 orders (Investing.com, GlobeNewswire.
Market reaction tracked the headline metrics: the intraday quote showed a price of $47.96 (change -2.02, -4.04%) and a market capitalization near $10.44B per Monexa AI quotes; the CEO sale and pending securities filings amplified volatility (Monexa AI, SEC Form 4 index.
What triggered Hims & Hers' Q2 revenue decline?#
The immediate cause was the sharp pullback in compounded GLP‑1 demand after Novo Nordisk ended the collaboration on June 23, 2025; that triggered subscriber off‑boarding, a mix shift to lower‑priced personalized prescriptions and an abrupt drop in revenue per subscriber, amplified by regulatory scrutiny and branded‑manufacturer litigation (GlobeNewswire, MarketScreener.
Monexa for Analysts
Go deeper on HIMS
Open the HIMS command center with real-time data, filings, and AI analysis. Upgrade inside Monexa to trigger your 7-day Pro trial whenever you’re ready.
Supporting that conclusion, the company disclosed a decline in GLP‑1 revenue from $230.0M to $190.0M quarter‑over‑quarter and a drop in revenue per subscriber to $74 from $84, which directly explains most of the sequential revenue gap (Investing.com transcript, GlobeNewswire.
Regulatory momentum—FDA statements on unapproved GLP‑1 compounding and an aggressive litigation campaign by branded manufacturers—narrowed non‑branded commercialization options, increasing churn risk for telehealth platforms selling compounded semaglutide alternatives (FDA, JDSupra.
Regulatory and legal fallout: Novo Nordisk, FDA guidance and securities filings#
Novo Nordisk’s litigation push against compounders and telehealth providers has been well‑documented; the company’s public pressure and subsequent termination of the collaboration with Hims & Hers altered third‑party supply dynamics and subscriber behavior (MarketScreener, Mediapost.
Concurrently, plaintiffs’ firms—Kessler Topaz, Levi & Korsinsky, The Gross Law Firm, Rosen Law Firm, Robbins Geller, Hagens Berman and others—have publicized a consolidated securities class action and an August 25, 2025 lead‑plaintiff filing deadline for purchasers during April 29–June 23, 2025 (PR Newswire, GlobeNewswire.
Securities litigation and regulatory enforcement create discrete burdens: increased legal expense, management distraction, and constrained strategic flexibility—factors that can compress multiples and raise the hurdle for new commercial initiatives in the near term (see class action reminders from plaintiff firms and press notices above).
Financial position, cash flow and capital allocation (what the numbers show)#
Hims & Hers closed FY 2024 with $1.48B in revenue and $126.04M in net income, reversing multi‑year net losses and producing a +8.54% net margin for the year, per company filings summarized by Monexa AI (Monexa AI.
Balance‑sheet strength improved materially in 2024: cash and equivalents of $220.58M, cash + short‑term investments $300.25M, and net debt of -$209.24M (net cash), while the current ratio registered 4.98x, providing near‑term liquidity to absorb legal and operational shocks (Monexa AI.
Operating cash flow and buybacks moved in tandem: net cash provided by operating activities of $251.08M and free cash flow of $198.33M in 2024, while the company repurchased $83.04M of common stock—a mix of shareholder return and balance‑sheet management ahead of heightened near‑term uncertainty (Monexa AI cash flow statement.
Tables and quantitative summary#
Below are compact tables for model inputs and quick comparison. Sources listed beneath each table are company financials aggregated by Monexa AI and Q2 commentary reported to the market.
Selected annual financials (FY 2024 vs FY 2023) — Source: Monexa AI
| Metric | FY 2024 | FY 2023 |
|---|---|---|
| Revenue | $1.48B | $872M |
| Gross profit | $1.17B | $714.95M |
| Operating income | $61.90M | -$29.45M |
| Net income | $126.04M | -$23.55M |
| Gross profit ratio | +79.45% | +81.99% |
(See Monexa AI for detailed line items and ratios: Monexa AI.
Analyst estimates (selected years) — Source: Monexa AI
| Year | Estimated revenue | Estimated EPS |
|---|---|---|
| 2025 | $2.34B | $0.59 |
| 2026 | $2.84B | $0.84 |
| 2027 | $3.40B | $1.13 |
| 2028 | $3.91B | $1.88 |
| 2029 | $4.47B | $2.39 |
Q1 vs Q2 GLP‑1 comparison (table formatted for quick extraction) — Sources: Investing.com, GlobeNewswire
| Metric | Q1 2025 | Q2 2025 | Sequential change |
|---|---|---|---|
| Compounded GLP‑1 revenue | $230.00M | $190.00M | -17.39% |
| Revenue per subscriber | $84 | $74 | -11.90% |
(Quarter figures and per‑subscriber metrics from company Q2 disclosures and earnings transcript: Investing.com transcript, GlobeNewswire.
Key financial takeaways (quick list)#
- FY 2024 turned profitable with net income $126.04M and +8.54% net margin — a marked improvement vs. prior years (Monexa AI.
- Q2 2025 revenue shock driven by GLP‑1: compounded GLP‑1 revenue down -17.39% q/q and revenue per subscriber down -11.90%, materially explaining the sequential gap (Investing.com.
- Liquidity and cash flow are supportive: cash + short‑term investments $300.25M, free cash flow $198.33M in 2024 — providing runway to manage litigation and retool go‑to‑market (Monexa AI.
- Valuation multiple compression is plausible: TTM price‑to‑sales 5.18x, TTM P/E 55.52x, and elevated forward P/E in 2025 indicate limited margin for upside absent a clear GLP‑1 recovery (Monexa AI.
What this means for investors: monitoring checklist and strategic implications#
Hims & Hers’ near‑term performance will hinge on a small set of observable variables: subscriber retention trends in GLP‑1 cohorts, revenue per subscriber, outcomes from regulatory inquiries or enforcement actions, and the pace and cost of legal defense. Track Q3 subscriber metrics and management’s ability to demonstrate medically justified, compliant compounding practices.
Insider activity and capital allocation matter: CEO Andrew Dudum’s reported sale (660,000 shares for ~$33.4M on August 7) is documented in SEC filings and coverage, and while the company says the sale was driven by tax and philanthropic reasons, investors will watch future insider transactions for confirmation of alignment (SEC Form 4 index, Morningstar MarketWatch.
Finally, legal and regulatory backdrops are not transitory here: branded manufacturers’ litigation and FDA guidance materially constrain compounding channels; Hims & Hers’ stated pivot to "personalized GLP‑1 treatments" must be demonstrably compliant to restore scale (FDA, MarketScreener.
Key takeaways#
Hims & Hers’ Q2 episode is a convergent event: an abrupt commercial slowdown in a core product line, an outsized insider sale, and active securities litigation. The company’s improved cash flow and FY 2024 profitability provide a buffer, but investor attention should remain focused on subscriber metrics, legal developments (including the August 25, 2025 lead‑plaintiff deadline), and management’s ability to operationalize a compliant GLP‑1 strategy while preserving margins and growth levers (PR Newswire, Monexa AI.